Clinical trials
Breast Cancer Stage III clinical trials
Below are recruiting breast cancer stage iii clinical trials, each written for real people, not researchers. We’re tracking 523 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06214195RecruitingPhase 3
Shengmai San to prevent heart damage from breast cancer therapy
This trial tests if a traditional Chinese medicine called Shengmai San can protect the heart during chemotherapy and targeted therapy for HER2-positive breast cancer. Patients take the supplement alongside standard treatment to see if it reduces the risk of heart problems.
Hangzhou, ZhejiangAges 18 years+ - NCT06593431RecruitingPhase 3
Treating limited spread pancreatic cancer with local therapy
This trial tests whether combining local treatments (like radiation or surgery) with standard care can help people with pancreatic cancer that has spread to only a few spots (oligometastatic disease). The goal is to improve outcomes for this specific group of patients.
Camden, New JerseyAges 18 years+ - NCT05325632RecruitingPhase 2
HER2 breast cancer vaccine plus chemo and targeted antibodies
This Phase 2 study tests a personalized immune-therapy vaccine made from your immune cells, given with weekly paclitaxel and HER2-targeted antibodies (trastuzumab and pertuzumab). It aims to improve treatment outcomes for people with HER2-positive breast cancer before standard local treatment (like surgery and radiation).
Tampa, FloridaAges 18 years+ - NCT06789653Recruiting
Using age-related proteins in early breast cancer
This study is testing a new way to use proteins in your blood that change with age to better understand early-stage breast cancer. It may help doctors personalize your care.
Chapel Hill, North CarolinaAges 22–66 - NCT07187726Recruiting
Trial to predict arm swelling risk during breast cancer radiation
This trial checks if telling you about your personal risk of arm swelling (based on a computer prediction) helps prevent it. You'll wear a compression sleeve during radiation and be monitored closely.
ArrasAges 18 years+ - NCT06261918Recruiting
Breast cancer study: linking metabolism to tumor behavior
This study looks at how your metabolism (things like blood sugar and cholesterol) might be linked to tumor genes and growth in people with breast cancer. The goal is to find new ways to treat the disease based on your metabolic profile. You may be eligible if you have locally advanced breast cancer (Stage II–III) and are willing to share your medical records.
RomaAges 18 years+ - NCT06393374RecruitingPhase 3
Study of a new drug combination for residual TNBC after initial treatment
This trial tests a new combination of two drugs (sacituzumab tirumotecan and pembrolizumab) compared to standard chemotherapy for people with triple-negative breast cancer that did not fully respond to initial treatment. It aims to see if this combination helps prevent cancer from coming back.
Mobile, AlabamaAges 18 years+ - NCT05232916RecruitingPhase 3
Vaccine for HER2-positive breast cancer after standard treatment
This trial tests a vaccine (GLSI-100) that may help prevent the return of HER2-positive breast cancer. It is given to patients who still had cancer cells after initial treatment with trastuzumab, or who had stage III disease and achieved a complete response.
Mobile, AlabamaAges 18–100 - NCT05464082RecruitingPhase 2
Collect tumor samples to guide early breast cancer recurrence care
This Phase 2 study tests a “precision” approach using tumor sample testing to help predict, prevent, and treat early metastatic recurrence in triple-negative or hormone-receptor–low, HER2-negative breast cancer. If you qualify, you’ll be asked to provide tumor tissue before (or in place of) standard chemotherapy, so researchers can learn which tumor features matter most.
Salt Lake City, UtahAges 18 years+ - NCT06923527RecruitingPhase 2
Testing ctDNA to start elacestrant in early breast cancer
This trial tests whether the drug elacestrant can help prevent recurrence in people with a type of breast cancer (ER+/HER2-) who have finished hormone therapy and have signs of cancer DNA in their blood (ctDNA positive) but no visible spread on scans.
New Haven, ConnecticutAges 18 years+ - NCT07311083Recruiting
Lifestyle program for triple-negative breast cancer patients
This study tests a lifestyle program (diet, exercise, and support) for women with triple-negative breast cancer who are getting chemotherapy plus immunotherapy before surgery. The goal is to see if healthy habits can help during treatment.
Essen, North Rhine-WestphaliaAges 18–75 - NCT06700369Recruiting
Lowering chemo with targeted therapy for HER2+ breast cancer
This study looks at whether using targeted therapy can reduce the amount of chemotherapy needed before surgery for HER2-positive breast cancer. It aims to find a safer, equally effective treatment plan.
Beijing, Beijing MunicipalityAges Any age - NCT07426822RecruitingPhase 2
Preventing Rash and Diarrhea with Capivasertib for Breast Cancer
This trial tests whether giving a combination of the drugs capivasertib and fulvestrant, along with medicines to prevent rash and diarrhea, can help treat hormone receptor-positive breast cancer that has a PIK3CA, AKT1, or PTEN change. It's for people whose cancer has spread or is locally advanced and can't be removed with surgery.
New Haven, ConnecticutAges 18 years+ - NCT05432856Recruiting
Track metabolic health habits during breast cancer treatment
This study follows how “metabolic health” patterns (like eating timing and daily activity) change over time during breast cancer care. It may help researchers learn which habit patterns are linked to better outcomes and comfort during chemotherapy.
Edmonton, AlbertaAges 18 years+ - NCT03053193Recruiting
Testing gene activity to guide breast cancer treatment
This study links breast tumor test results from MammaPrint and optional BluePrint (and full genetic data) with real-world clinical information to understand which new gene activity patterns matter. It may help future patients by improving how doctors use these tests to guide care.
Birmingham, AlabamaAges 18 years+ - NCT04501523RecruitingPhase 2
ctDNA-guided immunotherapy boost after chemotherapy for triple-negative breast cancer
This Phase 2 study checks whether a blood test that looks for cancer DNA (ctDNA) can help decide who should get an extra 12-month immunotherapy treatment after standard chemotherapy and surgery. It may help reduce the chance of the cancer coming back in people with triple-negative breast cancer.
Guandong, GuangdongAges 18–80 - NCT04614194RecruitingPhase 2
Blood and tumor markers to test response to abemaciclib
This trial studies how the immune system and other body signals in blood and tumor tissue relate to how well abemaciclib works before breast cancer surgery. The goal is to learn who benefits most from this medicine and why.
Dallas, TexasAges 18 years+ - NCT04680442RecruitingPhase 2
Keeping HER2 therapy when your heart function is weaker
This trial studies whether it’s safe to continue HER2-targeted breast cancer treatment (like trastuzumab, pertuzumab, or T-DM1) even when heart function (left ventricle) is reduced. It may help people avoid stopping a helpful cancer medicine because of heart concerns.
Porto Alegre, Rio Grande do SulAges Any age - NCT04803539RecruitingPhase 2/Phase 3
ctDNA-guided booster treatment after chemo for triple-negative breast cancer
This trial uses a blood test called ctDNA to see who is at higher risk after surgery and standard chemotherapy for triple-negative breast cancer. If your ctDNA test is positive, you may receive an extra “boost” treatment to help reduce the chance the cancer returns.
Guandong, GuangdongAges 18–80 - NCT07243002Recruiting
Patient outcomes with ribociclib or abemaciclib for early breast cancer
This study looks at how women and men with stage II or III HR+ HER2- breast cancer do when they start treatment with ribociclib or abemaciclib (combined with hormone therapy) after surgery. Researchers want to understand real-world experiences and results.
LondonAges 18 years+ - NCT05484973Recruiting
Portable scalp cooling to help prevent chemotherapy hair loss
This study tests whether a portable cooling cap system can reduce hair loss for women with breast cancer who are planning certain chemotherapy treatments. It may help you keep more of your hair while you receive chemotherapy.
Tucson, ArizonaAges 21 years+ - NCT05496829Recruiting
Improving how people take breast-cancer and heart medicines
This trial tests an intervention to help improve how equitably people take their prescribed breast cancer hormone therapy and heart-related prevention medicines. It may help if you have had trouble taking these medications as directed.
New York, New YorkAges 18–99 - NCT05502224Recruiting
Program for ongoing fatigue in young cancer survivors
This study tests a multidisciplinary program to help reduce ongoing fatigue after acute cancer treatment. It is for younger adults who still feel at least moderate fatigue about a month after finishing treatment.
BrusselsAges 18–39 - NCT05522959Recruiting
Exercise rehab for breast cancer recovery
This trial tests an exercise-based rehabilitation program for people who have had early-stage breast cancer and are finishing or currently getting standard treatments like chemotherapy, surgery, radiation, or targeted drugs. It may help improve heart and breathing fitness during recovery.
Toronto, OntarioAges 18 years+
Hear when a new Breast Cancer Stage III trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for breast cancer stage iii?
- Yes. Clin2 currently lists 523 recruiting breast cancer stage iii studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a breast cancer stage iii trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a breast cancer stage iii trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Breast Cancer Early Stage Breast Cancer (Stage 1-3)
- Anatomic Stage III Breast Cancer AJCC v8
- Prognostic Stage III Breast Cancer AJCC v8
- Breast Cancer (Triple Negative Breast Cancer (TNBC))
- Anatomic Stage IV Breast Cancer AJCC v8
- Anatomic Stage II Breast Cancer AJCC v8
- Non-small Cell Lung Cancer Stage III
- Anatomic Stage I Breast Cancer AJCC v8
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.